Vectura Group plc (LSE: VEC) (“Vectura”, “the Company” or “the Group”) today announced a key leadership appointment to drive business development and growth as the Company continues with its strategy to become a leading inhalation specialist in the pharmaceutical services space.
Chippenham, UK – 09 March 2020: Vectura Group plc (LSE: VEC) (“Vectura”, “the Company” or “the Group”) today announced a key leadership appointment to drive business development and growth as the Company continues with its strategy to become a leading inhalation specialist in the pharmaceutical services space.
Mark Bridgewater has been appointed as Chief Commercial Officer, a newly-created role focussed on helping the Company to transform into a successful contract development and manufacturing organisation (CDMO). In his new position, Mr Bridgewater will implement strong sales processes in order to secure new business, as well as building out a world-class commercial team and driving Vectura’s brand market presence.
Will Downie, CEO of Vectura, said: “I am thrilled to have Mark join Vectura, where he will play a pivotal role in driving the future growth of the organisation. He comes to the Company with an impressive track record of delivering sustained growth and market success in each of his previous roles. His versatile leadership skills and growth mindset will help accelerate the transformation of the company into a true leader in the outsourcing space.”
Mr Bridgewater added: “I am delighted to be joining Vectura at such an exciting time, as the Company pivots to become a leader in the CDMO market. I look forward to working with my new colleagues to drive value for customers, employees and shareholders.”
Mr Bridgewater has more than 20 years of experience in medical device and pharmaceutical services. Prior to joining Vectura, he was VP Business Development and Account Management for Europe and Asia at Flex, a global design, engineering and manufacturing organisation. Previously, he was VP Global Business Development, Advanced Delivery Technologies at Catalent, and earlier in his career worked as Head of Global Manufacturing Services at Wockhardt and Senior Business Manager, Italy, for Patheon.
- Ends-
For more information, please contact:
Vectura Group plc
David Ginivan - VP Corporate Communications +44 (0)7471 352 720
Elizabeth Knowles - VP Investor Relations +44 (0)7767 160 565
Consilium Strategic Communications
Mary-Jane Elliott / Sue Stuart / David Daley +44 (0)20 3709 5700
About Vectura
Vectura is a provider of innovative inhaled drug delivery services that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies.
Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.
For further information, please visit Vectura’s website at www.vectura.com
Forward-looking statements
This press release contains forward-looking statements, including statements about the commercialisation of products. Various risks may cause Vectura’s actual results to differ materially from those expressed or implied by the forward looking statements, including: commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise.
